Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Hidden Trials” In The Age Of Transparency: ClinicalTrials.gov Director Sees Room For Improvement

This article was originally published in RPM Report

Executive Summary

The global push towards clinical trial registration and transparency hasn’t ended the problem of “hidden trials,” the head of NIH’s ClinicalTrials.gov cautions. But the existence of registries helps better analyze the problem and offers some fairly simple steps to get closer to the goal of assuring that all clinical trials are available to the public.

You may also be interested in...



ClinicalTrials.gov Compliance: Absent Regs, Enforcement Of Reporting Still Lags

The National Institutes of Health is still drafting regulations, but Rep. Markey’s TEST Act, which would impose more extensive reporting requirements, has won praise from stakeholders for some of its definitional details. In an election season, its prospects for passing are slim, but aspects of the legislation could serve as a model for pending regulations.

Virtual Advisory Committees: US FDA Clears A Big Test With OxyContin Meeting

Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.

Trump’s Drug Pricing Plan: The Headlines Are The Goal – But Also A Threat

The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel